Checkpoint Capital L.P. Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001977548
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q1 2025 · 14 positions · Total reported value $182.27M · Top-10 concentration 98.2% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 25.0% · 2 new · 0 cut · 0 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
In its Q1 2025 13F filing, Checkpoint Capital L.P. disclosed 14 equity positions with a combined reported value of $182.27M. The filing implies a focused portfolio: its ten largest positions account for 98.2% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q1 2025 were ARGX ($68.06M), RYTM ($48.06M), RVMD ($13.86M). By sector, the heaviest allocations are Health Care 91.9%, Other 8.1%. Versus the prior quarter, allocation shifted toward Health Care (+1.5pp) and away from Other (-1.5pp).
Versus the prior quarter, Checkpoint Capital L.P. opened 2 new positions, trimmed 0 and fully exited 0, a turnover rate of 25.0% of positions. The portfolio's overlap with the prior quarter was 43% of names.
The largest new positions opened in Q1 2025 were PTGX ($8.47M), SEPN ($4.78M), CORT ($571.10K).
Of the 7 positions fully exited versus the prior quarter, the largest were PHAT ($18.47M), AXSM ($14.79M), AVDL ($10.56M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q1 2025)
- PTGX PROTAGONIST THERAPEUTICS INC · $8.47M
- SEPN SEPTERNA INC · $4.78M
- CORT CORCEPT THERAPEUTICS INC · $571.10K
- IMCR IMMUNOCORE HLDGS PLC · $267.36K
- RAPT RAPT THERAPEUTICS INC · $133.99K
Fully Exited (vs previous quarter)
- PHAT PHATHOM PHARMACEUTICALS INC · prev qtr: $18.47M
- AXSM AXSOME THERAPEUTICS INC. · prev qtr: $14.79M
- AVDL AVADEL PHARMACEUTICALS · prev qtr: $10.56M
- PLRX PLIANT THERAPEUTICS INC · prev qtr: $7.05M
- TRVI TREVI THERAPEUTICS INC · prev qtr: $4.47M · history
- ATYR ATYR PHARMA INC · prev qtr: $1.57M
- CYTK CYTOKINETICS INC · prev qtr: $940.80K · history
Insider Transactions (Form 4)
Latest Checkpoint Capital L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Checkpoint Capital L.P., based in San Francisco, CA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 6 positions worth $389.76M in total. HoldingsHub carries 11 quarters of its filings (Q4 2023–Q2 2026).
Firm Snapshot
- Headquarters: SAN FRANCISCO, CA, United States
- SEC registration: 801-134055 (status: Approved), registered 2025-08-19
- Regulatory AUM (Form ADV): $333.78M as of 2026-03-27
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 1 private funds, of which 1 hedge funds
- Website: checkpointlp.com
Portfolio Structure
- 6 positions · $389.76M reported value (Q2 2026)
- Top 10 holdings = 100.0% of reported value
- Largest position: RYTM (RHYTHM PHARMACEUTICALS INC) at 33.8%
- Average position size: $64.96M
Sector Tilt
- Health Care 100.0%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 3 added, 3 reduced, 2 exited
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
115.00K | $68.06M | 37.34% | Add | |
| 2 |
|
907.24K | $48.06M | 26.37% | Add | |
| 3 |
|
392.01K | $13.86M | 7.61% | Add | |
| 4 |
|
172.90K | $12.35M | 6.78% | Add | |
| 5 |
|
243.31K | $12.08M | 6.63% | Add | |
| 6 |
|
175.18K | $8.47M | 4.65% | New | |
| 7 |
|
730.72K | $4.86M | 2.67% | Add | |
| 8 |
|
824.88K | $4.78M | 2.62% | New | |
| 9 |
|
136.60K | $3.74M | 2.05% | Add | |
| 10 |
|
2.02M | $2.78M | 1.53% | Add | |
| 11 |
|
104.38K | $2.25M | 1.23% | Reduce | |
| 12 |
|
5.00K | $571.10K | 0.31% | New | |
| 13 |
|
9.01K | $267.36K | 0.15% | New | |
| 14 |
|
109.83K | $133.99K | 0.07% | New | |
FAQ
What did Checkpoint Capital L.P. buy in 2025-Q1?
In its 2025-Q1 13F filing, Checkpoint Capital L.P. reported 14 equity positions worth $182.27M in aggregate; its largest disclosed positions were ARGX ($68.06M), RYTM ($48.06M), RVMD ($13.86M).
How large is Checkpoint Capital L.P.'s portfolio?
Checkpoint Capital L.P. reported $182.27M of long equity holdings across 14 positions as of 2025-Q1. Top-10 holdings account for 98.2% of reported value.
What is Checkpoint Capital L.P.'s investment style?
HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.